



## Preferred Drug List

### NEW DRUG REVIEW

**Proprietary Name:** Erivedge™

**Common Name:** vismodegib

**PDL Category:** Antineoplastics - Antimetabolites

<u>Comparable Products</u>	<u>Preferred Drug List Status</u>
N/A	

#### Summary

**Indications and Usage:** Indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and radiation.<sup>1</sup>

**Mechanism of Action:** Inhibitor of the Hedgehog pathway that is active in most basal cell cancers.<sup>1</sup>

**Dosage Forms:** Capsules: 150mg

**Recommended Dosage:** 150mg once daily until disease progression or unacceptable toxicity.<sup>1</sup>

**Common Adverse Drug Reactions:** Muscle spasms, alopecia, dysgeusia, weight loss, fatigue, nausea, diarrhea, decreased appetite, constipation, arthralgias, vomiting, and ageusia.<sup>1</sup>

**Contraindications:** None.<sup>1</sup>

**Manufacturer:** Genentech, Inc.

**Analysis:** Erivedge™ is indicated for the treatment of adults with advanced basal cell carcinoma. A single, multi-center, open-label study was used to gain FDA approval. The primary efficacy outcome measure was Objective Response Rate (ORR). Ninety-six patients were evaluable for ORR. Of the 33 patients with metastatic disease, 30 percent experienced a partial response. No patients experienced a complete response. Of the 63 patients with locally advanced disease, 43 percent of patients experienced a complete or partial response. It is recommended that Erivedge™ be added to the Recommended Drug List as a non-recommended drug, as it is only intended to be used in patients with metastatic or locally advanced disease or in patients who are not candidates for alternative therapy.

**IME Recommendation:**  Preferred Drug  Recommended Drug  
 Non-Preferred Drug  Non-Recommended Drug  
 Preferred Drug with Conditions

1. Erivedge™ [package insert]. South San Francisco, CA: Genentech, Inc.; 2012.